AVEO stock: buy or sell?
January 24th, 2020
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF\u002Fc-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study.
Should I buy AVEO stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with AVEO Pharmaceuticals stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is AVEO stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we collected 8 ratings published for AVEO stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-10||Piper Jaffray Companies||n/a||Overweight|
AVEO stock analysis
AVEO shares slipped -1.67% to $0.59 yesterday.
AVEO shares slipped -1.67% to $0.59 yesterday. Since last November when AVEO stock price broke down the SMA200d line, it slid $-0.30 per share (-33.71%). AVEO is retaking the upward trend marking a new rising bottom heading to break out over $0.70.
AVEO shares collapsed -7.81% this week, ending at $0.59. Early January AVEO boosted a dazzling 7.46% in just one week.
Since SMA20w and SMA40w crossed up last week, AVEO price slid a -11.94%. Since early November 2019, when AVEO stock price broke down the 40-weeks moving avarage line, it slid $-0.30 per share (-33.71%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.
AVEO stock price history
AVEO IPO was on March 12th, 2010 at $8.25 per share1. Since then, AVEO stock lost a -92.80%, with a yearly average of -10.30%.
1: Adjusted price after possible price splits or reverse-splits.
AVEO stock historical price chart
AVEO stock reached 52-week highs at $1.86, and all-time highs 2011-07-06 with a price of 21.55.
AVEO stock price target is $1.50Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we found 7 price forecasts for AVEO stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-10||Piper Jaffray Companies||Raises Target||$3.00||$4.00||33.3%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, AVEO missed the estimates of the analysts and reported a spooky EPS of $-0.03 per share when experts were expecting $-0.06.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a spooky correction of -28.63% to $5.41 million dollars. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) skyrocketed a 759.44% to -98.52%.
|2013||$1.29 M||-||$-107.03 M-8296.9%||-|
|2014||$18 M||1,304.88%||$-52.74 M-291.0%||-50.73%|
|2015||$19 M||4.97%||$-15.00 M-78.9%||-71.56%|
|2016||$2.52 M||-86.78%||$-26.89 M-1069.1%||79.23%|
|2017||$7.58 M||201.35%||$-65.03 M-858.0%||141.85%|
|2018||$5.41 M||-28.63%||$-5.33 M-98.5%||-91.80%|
Quarterly financial resultsAVEO posted $1.48 M in revenues for 2018-Q4, a -39.89% decline compared to previous quarter. Reported quarter income marked $21.82 million with a profit margin of 1,471.21%. Profit margin climbed a 2,369.59% compared to previous quarter when profit margin was -898.38%. When comparing revenues to same quarter last year, AVEO Pharmaceuticals sales marked a super good gain and rocketed a 1,708.54%.
|2017-Q1||$2.53 M||-||$-8.84 M-349.4%||-|
|2017-Q2||$0.35 M||-86.13%||$-33.29 M-9484.3%||276.58%|
|2017-Q3||$4.61 M||1,214.53%||$-26.40 M-572.1%||-20.71%|
|2017-Q4||$0.08 M||-98.22%||$3.50 M4267.1%||-113.26%|
|2018-Q1||$1.03 M||1,151.22%||$-8.99 M-876.0%||-356.87%|
|2018-Q2||$0.43 M||-57.80%||$4.00 M924.7%||-144.55%|
|2018-Q3||$2.47 M||469.75%||$-22.16 M-898.4%||-653.52%|
|2018-Q4||$1.48 M||-39.89%||$21.82 M1471.2%||-198.44%|
AVEO ownershipWhen you are planning to invest in a stock, it's worth to check its ownership structure.
AVEO Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
For a better understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, January 24th, 2020|
|Day range||$0.58 - $0.62|
|Average true range||$0.03|
|50d mov avg||$0.66|
|100d mov avg||$0.75|
|200d mov avg||$0.75|
AVEO performanceTo better understand AVEO performance you must compare its gains with other related stocks in same sector or industry. For AVEO Pharmaceuticals, the benchmark is made against .